Evidence map›Paper›PMID 39920302›Full record

ArticleEuropean radiology2025

Prognostic impact of late gadolinium enhancement granularity in non-ischemic dilated cardiomyopathy.

Trecy Gonçalves, Jérôme Garot, Solenn Toupin, Valérie Bousson, Francesca Sanguineti, Myriam Akodad, Suzanne Duhamel, Stéphane Champagne, Antoinette Neylon, Thierry Unterseeh and 10 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in European radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Role of cardiovascular magnetic resonance in diagnosis and management of muscular dystrophies.Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Trecy GonçalvesUniversité Paris Cité, Service de Cardiologie, Hôpital Lariboisière-Assistance Publique des Hôpitaux de Paris (AP-HP), 75010, Paris, France.
Jérôme GarotInstitut Cardiovasculaire Paris Sud, Cardiovascular Magnetic Resonance Laboratory, Hôpital Privé Jacques CARTIER, Ramsay Santé, 91300, Massy, France. jgarot@angio-icps.com.ORCID http://orcid.org/0000-0003-3714-1256
Solenn ToupinSiemens Healthcare France, 93200, Saint-Denis, France.
Valérie BoussonUniversité Paris Cité, Service de Radiologie, Hôpital Lariboisière-Assistance Publique des Hôpitaux de Paris (AP-HP), 75010, Paris, France.
Francesca SanguinetiInstitut Cardiovasculaire Paris Sud, Cardiovascular Magnetic Resonance Laboratory, Hôpital Privé Jacques CARTIER, Ramsay Santé, 91300, Massy, France.
Myriam AkodadInstitut Cardiovasculaire Paris Sud, Cardiovascular Magnetic Resonance Laboratory, Hôpital Privé Jacques CARTIER, Ramsay Santé, 91300, Massy, France.
Suzanne DuhamelInstitut Cardiovasculaire Paris Sud, Cardiovascular Magnetic Resonance Laboratory, Hôpital Privé Jacques CARTIER, Ramsay Santé, 91300, Massy, France.
Stéphane ChampagneInstitut Cardiovasculaire Paris Sud, Cardiovascular Magnetic Resonance Laboratory, Hôpital Privé Jacques CARTIER, Ramsay Santé, 91300, Massy, France.
Antoinette NeylonInstitut Cardiovasculaire Paris Sud, Cardiovascular Magnetic Resonance Laboratory, Hôpital Privé Jacques CARTIER, Ramsay Santé, 91300, Massy, France.
Thierry UnterseehInstitut Cardiovasculaire Paris Sud, Cardiovascular Magnetic Resonance Laboratory, Hôpital Privé Jacques CARTIER, Ramsay Santé, 91300, Massy, France.
Thomas HovasseInstitut Cardiovasculaire Paris Sud, Cardiovascular Magnetic Resonance Laboratory, Hôpital Privé Jacques CARTIER, Ramsay Santé, 91300, Massy, France.
Lounis HamziUniversité Paris Cité, Service de Radiologie, Hôpital Lariboisière-Assistance Publique des Hôpitaux de Paris (AP-HP), 75010, Paris, France.
Alexandre UngerUniversité Paris Cité, Service de Cardiologie, Hôpital Lariboisière-Assistance Publique des Hôpitaux de Paris (AP-HP), 75010, Paris, France.
Jeremy FlorenceUniversité Paris Cité, Service de Cardiologie, Hôpital Lariboisière-Assistance Publique des Hôpitaux de Paris (AP-HP), 75010, Paris, France.
Raphael MiraillesUniversité Paris Cité, Service de Cardiologie, Hôpital Lariboisière-Assistance Publique des Hôpitaux de Paris (AP-HP), 75010, Paris, France.
Antoine BondueUniversité Libre de Bruxelles (ULB), Départment de Cardiologie, CUB Hôpital Erasme, 1070, Bruxelles, Belgique.
Jean Guillaume DillingerUniversité Paris Cité, Service de Cardiologie, Hôpital Lariboisière-Assistance Publique des Hôpitaux de Paris (AP-HP), 75010, Paris, France.
Patrick HenryUniversité Paris Cité, Service de Cardiologie, Hôpital Lariboisière-Assistance Publique des Hôpitaux de Paris (AP-HP), 75010, Paris, France.
Philippe GarotInstitut Cardiovasculaire Paris Sud, Cardiovascular Magnetic Resonance Laboratory, Hôpital Privé Jacques CARTIER, Ramsay Santé, 91300, Massy, France.
Théo PezelUniversité Paris Cité, Service de Cardiologie, Hôpital Lariboisière-Assistance Publique des Hôpitaux de Paris (AP-HP), 75010, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesWe aimed to assess the additional prognostic value of the concept of "late gadolinium enhancement (LGE) granularity" in non-ischemic dilated cardiomyopathy (DCM) patients to predict all-cause death.

methodsBetween 2008 and 2021, we conducted a bicentric retrospective study including all consecutive DCM patients referred for Cardiovascular Magnetic Resonance (CMR). The primary outcome was all-cause death. Cox regressions were performed to determine the prognostic value of LGE findings.

resultsOf 1668 DCM patients recruited (age 52 ± 8 years, 54% male), 268 (16%) died after a median (interquartile range) follow-up of 9 (7-12) years. In DCM patients with LGE (N = 472), the LGE extent, the septal location, and its presence in multiple areas were independently associated with death after adjustment for all prognostic variables (adjusted hazard ratio (HR): 4.27, 95% CI: 2.22-8.22; HR: 5.74, 95% CI: 3.35-9.85; and HR: 4.38, 95% CI: 2.08-9.22 respectively; all p < 0.001). The LGE granularity model combining all these LGE features showed the best improvement in model discrimination and reclassification over traditional prognostic variables, including the left ventricular ejection fraction (LVEF) value (C-statistic improvement: 0.14; net reclassification improvement = 64.3%; integrative discrimination index = 29.0%; all p < 0.05).

conclusionIn a large cohort of DCM patients, a LGE granularity model combining LGE extent, location and multiple areas had additional prognostic value above traditional prognostic variables including the LVEF value to predict all-cause death. KEY POINTS: Question Assessment of late gadolinium enhancement (LGE) is recommended in non-ischemic dilated. cardiomyopathy (DCM) patients to stratify the risk of death, but other LGE characteristics are not currently considered. Findings The concept of "LGE granularity," including the extent, location, and number of areas, provides additional prognostic value, especially in predicting all-cause mortality. Clinical relevance "LGE granularity" could play a crucial role not only in guiding the decision to implant a defibrillator in DCM patients but also in providing more personalized management, such as enhanced cardioprotective treatments, for those with high-risk LGE characteristics.

Indexed as

Cardiomyopathy, DilatedContrast MediaGadoliniumMagnetic Resonance ImagingMagnetic Resonance Imaging, CineAdultFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesContrast MediaGadoliniumAdditional prognostic valueCardiovascular magnetic resonanceLate gadolinium enhancementNon-ischemic dilated cardiomyopathyPrognosis

Identifiers

PMID39920302

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.